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Salmonel la strains have great potential as live carriers of  heterologous antigens to induce 
immunity against a variety of  infectious diseases. However, the amount of heterologous 
antigen required to induce an adequate immune response may be toxic.for the bacterium 
and result in cell death, overattenuation r loss of expression of the heterologous antigen. 
To solve this problem an expression vector was developed with a strong promoter located 
on a DNA fragment which is inverted at random. Antigen is only expressed inone particular 
orientation of the promoter. Thus a bacterial population harbouring the plasmid will consist 
of a subpopulation which does not produce heterologous antigen, and is therefore not 
affected in growth, persistence and dissemination within the host. Further, this 
non-producing population will continuously segregate antigen-producing bacteria. To 
evaluate the system, CtxB was used as a model antigen. Analysis of the plasmid DNA 
isolated from Salmonel la revealed a selection against he promoter orientation that directs 
transcription of the ctxB gene. In spite of  this', the vector was stably maintained in vivo 
and induced CtxB-specific IgA and IgG in mice. These results indicate that this kind of 
expression vector may offer a solution to the problem of unstable expression of foreign 
antigens in live bacterial vaccine strains. 
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Attenuated Salmonella strains expressing heterologous 
antigens have been shown to be able to induce mucosal, 
humoral and cell-mediated immunity against these 
antigens 1.With respect o cell-mediated immunity, both 
class I and II MHC-restricted cytotoxic T cells directed 
against heterologous antigens have been detected 2 4. 
Furthermore, in animal models protective immunity has 
been induced with a number of Salmonella-recombinant 
strains against bacterial, viral and protozoal infections 4-6. 
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Live Salmonella vaccine strains have been accepted for 
use in humans. An oral human typhoid vaccine based 
on Salmonella typhi strain Ty21a, a galE mutant, has 
been licensed in many countries after it was shown to be 
efficacious in field trials v. Other more defined attenuated 
Salmonella strains have been constructed, such as aroA 
and cya, crp mutants. These strains have been shown to 
be safe and immunogenic n a number of animal models. 
Salmonella strains attenuated by aro mutations have been 
shown to be safe even in immune-suppressed animals I.
S. t)Thi aroA, purA and S. oThi aroC, D strains have 
undergone phase 1 clinical trials in humans 8'9. 
Clearly, Salmonella strains have great potential as live 
carriers to induce immunity against a variety of infectious 
diseases. However, the amount of heterologous antigen 
required to obtain an adequate immune response is often 
toxic for the bacterium, and this forms a major obstacle 
to the use of recombinant Salmonella strains. In order 
to solve this problem, an expression system was 
developed, based on an invertible promoter, which results 
in high-level expression of the antigen of interest in only 
a minor part of the bacterial population 1°. If the amount 
of antigen produced is toxic for the bacterium, it will 
stop growing, but the non-producing part of the 
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population will continue to grow and segregate new 
antigen producers. Here we describe the construction of
this expression vector and its evaluation in a mouse 
model using the B subunit of cholera toxin (CtxB) as a 
model antigen. 
MATERIALS AND METHODS 
Bacterial strains, plasmids and media 
Escherichia coli strain DH5~ (BRL Life Technologies, 
Breda, The Netherlands) was used as a host for all 
plasmid constructions. Before introduction into the 
Salmonella typhimurium vaccination strain SL326111, 
plasmids were passaged through the restriction-deficient, 
modification-proficient S. typhimurium strain SL5283. All 
bacteria were grown in NZCYM 12 aerobically at 37°C, 
unless indicated otherwise. Ampicillin was used at 
100 #g ml- 1. 
DNA manipulations 
Isolation of plasmid DNA, preparation of DNA 
fragments and ligations were carried out using standard 
methods 12. Plasmids were introduced into bacteria by 
electroporation using the Biorad Gene Pulser (Bio-Rad, 
Richmond, CA, USA) as follows: overnight cultures were 
diluted 1:100 in NZCYM and grown aerobically at 37°C 
to mid-log phase. The cells were subsequently harvested 
by centrifugation a d washed twice with ice-cold distilled 
water. Finally, the cells were resuspended to 101° 
cellsm1-1 in distilled water containing 10% (w/v) 
glycerol, frozen in dry ice and stored at - 70°C until use. 
For electroporation, DNA was precipitated, resuspended 
in distilled water and subsequently mixed with 109 cells 
in an ice-cooled cuvette and electroporated at 2.5 kV, 
25#F and 200t2. Immediately after electroporation 
l ml of NZCYM was added and the cells were 
subsequently incubated aerobically for 30min at 37°C. 
Aliquots were plated on NZCYM-agar plates containing 
ampicillin and incubated at 37°C. 
Immunization of mice and in vivo stability of pYZ17 
For oral immunization, bacteria from logarithmically 
growing cultures were harvested by centrifugation, 
washed in phosphate-buffered saline (PBS) and resuspen- 
ded to a cell concentration f 2 x 10 l° cells ml- 1 in 10% 
NaHCO 3. Subsequently, 6-week-old female Balb/c mice 
received two successive oral immunizations with 10 l° 
bacteria at days 1 and 4 followed by two successive 
booster immunizations with the same number of bacteria 
at days 32 and 36. At days 11, 18, 25, 32 and 60 two mice 
per group were bled and their spleens and guts were 
removed. Gut-washes were obtained by washing the 
complete gut-segment distal from the stomach with 1 ml 
PBS, centrifuging the samples for 10min at 10000 
rev min-1 and collecting the supernatants. Gut-washes 
and sera were stored at -20°C until tested by ELISA. 
The spleens were homogenized and the stability of pYZ 17 
was determined by comparing the number of viable 
bacteria that could be recovered on McConkey agar 
plates with and without ampicillin (100 #g ml-1). 
Essentially the same procedure was followed for 
intraperitoneal (i.p.) immunization, except hat bacteria 
were suspended in PBS to a cell concentration f 2 × l0  6 
cells ml-1, and mice were immunized with 106 bacteria 
intraperitoneally (i.p.) at days 4 and 32. 
ELISA 
[3-1actamase ELISA. /Mactamase (TEM R +, Boeh- 
ringer Mannheim, Germany) was diluted in 0.1 M 
phosphate buffer, pH 8.1, to a protein concentration of
2.5~gm1-1 and adsorbed onto 96-well high-binding 
microtitre plates (Costar E.I.A./R.I.A. plate HB, Cam- 
bridge, USA) by overnight incubation at 4°C. After 
washing with demineralized water containing 0.05% 
Tween-80, plates were blocked with PBS containing 5% 
fetal calf serum (FCS), 5% NaCI and 0.1% Tween-20. 
Plates were washed with 0.05% Tween-80 containing 
demineralized water and each well was incubated with 
100~1 dilutions of the sera or gut-washes. After 
incubation for 1 h at 37°C, the plates were washed twice 
and the wells were incubated with goat anti-mouse IgG 
or IgA HRP-conjugates (Southern Biotechnology Inc., 
Birmingham, UK) diluted 8000 times. Binding of the 
conjugate was detected by addition of 100/A of a 
TMB/DONS-based substrate solution to each well. After 
10min at room temperature, 100#1 2M HzSO 4 was 
added to stop the colour reaction. The absorbance at 
450 nm was determined in a Titertek Multiscan (Titertek, 
ICN Biomedicals, Amsterdam, The Netherlands). The 
titre was defined as the highest dilution of test samples 
at which the A45o was higher than the mean A45o + three 
times s.d. of the corresponding samples from Balb/c mice 
immunized i entically with SL3261 without pYZ17. 
LPS-ELISA. The ELISA for LPS differed from the 
fl-lactamase ELISA only in the coating step, which was 
performed in 0.11 M acetate buffer, pHS.5, containing 
5.0/~g m1-1 S. typhimurium LPS (Sigma, cat. no. L6511, 
Axel, The Netherlands) and the anti-IgG and IgA 
HRP-conjugate dilutions employed (1:4000). The titre 
was defined as the highest serum dilution at which the 
A45 o was  higher than the mean A45o+three times 
standard eviation (s.d.) of preimmune sera. 
CtxB-ELISA. CtxB (List Biological Labs, Campbell, 
CA, USA) was diluted in PBS to a concentration of
5.0/tg ml-1 and adsorbed to the microtitre plates. The 
used anti-IgG and IgA conjugates were diluted 10000 
and 4000 times respectively. All the other conditions were 
as described for the fl-lactamase ELISA. 
Western blot analysis of recombinant bacteria 
Overnight cultures were diluted ten times in NZCYM 
and incubated aerobically until the absorbance of the 
culture at 550 nm reached 1.0. Aliquots of bacteria were 
pelleted, resuspended in 100 #1 sample buffer 13 and boiled 
for 20min. Samples of 10/A were separated on 15% 
SDS-PAGE and subsequently transferred to nitro- 
cellulose. After blocking with 0.5% Tween-80 in PBS for 
30min the blots were incubated at room temperature 
with a goat-anti-CtxB serum (List Biological Labs, 
Campbell, CA, USA) diluted 500 times in PBS containing 
0.5% Tween-80 and 0.5% low-fat milk powder. After 
washing three times over a period of 30min in PBS 
containing 0.5% Tween-80, the blot was incubated for 
1 h at room temperature with horseradish peroxidase- 
conjugated protein A (Amersham, Den Bosch, The 
Netherlands) diluted 2500 times with 0.5% Tween-80 in 
PBS. After three washings, the blot was developed in a 
TMB/DONS-based substrate. 
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RESULTS 
Construction and characterization of pYZI7 
Plasmid pYZ17 is an expression plasmid with an 
invertible promoter based on the bacteriophage Mu Gin 
system. The Gin invertase of phage Mu initiates 
spontaneous G segment inversion on phage Mu genome, 
which takes place between two 34 bp inverted repeat (IR) 
sequences 14. The size of the invertible segment is not a 
crucial factor in the inversion process, a G segment as 
small as 40 bp is still inverted, and the left (L) and right 
(R) IR sequences are equivalent in terms of their roles in 
the recombination process and can therefore substitute 
for each other 15. Based on these observations, an 
invertible promoter can be constructed by inserting a 
promoter fragment between two identical IR sequences. 
Plasmid pYZ17 is a derivative of pYZ16a (Yan and 
Meyer, manuscript in preparation), which has the 
following features; a promoterless DNA fragment coding 
for phage Mu Gin invertase, a clts857 gene fragment 
coding for temperature-sensitive lambda cl repressor, a 
fd transcriptional terminator downstream and an rrnB 
T1 transcriptional terminator upstream of clts857 
fragment, a promoterless cholera toxin subunit B 
fragment sequence, origin of replication and ampicillin 
resistance gene from pBR328. Plasmid pYZ17 (Figure 1) 
was constructed by introducing an XhoI IR-PL-IR 
module into the single XhoI site on pYZ16a. To construct 
the IR-PL-IR module, the lambda leftward promoter PL 
was isolated from pLC283316 as an ~250bp XhoII 
fragment and ligated at both ends with a synthetic IR 
sequence flanked by BclI/XhoI sites: 5'-GATCATTTA- 
CCGTTTCCTGTAAACCGAGGTTTTGGATAAC-3'. 
After ligation, the IR-PL-IR module was inserted into 
pYZ16a. In the resulting plasmid, pYZ17, antigen (CtxB) 
expression can only occur in one orientation of the PL 
promoter (designated the 'ON' orientation). Besides a 
correct orientation of the PL promoter, expression of 
CtxB requires the bacteria containing pYZ17 to be grown 
at temperatures higher than 28°C to inactivate the 
thermosensitive repressor of PL. 
Expression of CtxB was analysed on Western blots, 
after growing strain SL3261 harbouring pYZ17 at 28 and 
37°C. As expected, CtxB could not be detected when 
bacteria were grown at 28°C, but was clearly induced at 
37°C (Figure 2). 
If there is no selection against a particular orientation 
of the PL promoter, one expects that in a bacterial 
population habouring pYZ17, 50% of the plasmids will 
contain the PL promoter in the 'ON' orientation. However, 
if transcription driven by the PL promoter in a particular 
orientation (most probably the ON orientation) is 
detrimental, the percentage of plasmids with this 
orientation will be smaller than 50%. To estimate the 
fraction of pYZ17 molecules in the bacterial population 
which contained PL in the oy orientation, plasmid DNA 
was isolated from bacteria grown at 28 and 37°C, and 
subsequently digested with EcoRI. Plasmid pYZ17 
contains two EeoRI restriction sites (Figure 1), one of 
which is located between the two inverted repeats (IR) 
just downstream ofthe PL promoter. Digestion of pYZ 17 
with EcoRI should result in fragments of 5.0 and 1.9 kb 
for plasmids containing the PL promoter in the 'OFF' 
orientation and 4.7 and 2.2kb for the on orientation. 
Analysis of EcoRI-digested pYZ17 DNA derived from 
bacteria grown at 37°C revealed that a small fraction of 
fdT  
EcoRI 
T1 PL 
pYZ1 7 
(6.9 kb) 
EcoRI 
Figure 1 Plasmid pYZ17 containing an invertible promoter for CtxB 
expression. PL, leftward promoter of bacteriophage lambda; IR, inverted 
repeat; T1, rrnB T1 transcription terminator; fd T, transcription terminator 
fd T; amp, ampicillin resistance gene; gin, invertase gene; clts, phage 
lambda temperature-sensitive repressor protein gene; ctxB cholera toxin 
B subunit gene. The two EcoRI sites which can be used to determine 
the orientation of the PL promoter are indicated. Shown is pYZ17 with 
the e L promoter in the OFF orientation 
CtxB 
123 
Figure 2 CtxB expression by SL3261(pYZ17) at 28 and 37'C. Total cell 
lysates containing equal quantities of bacteria were subjected to 
SDS-PAGE, followed by Western blotting using a CtxB-specific serum. 
Lane 1, SL3261 grown at 37°C; lane 2, SL3261(pYZ17) grown at 28°C; 
lane 3, SL3261(pYZ17) grown at 37°C 
pYZ17 plasmids contained PL in the ON orientation, 
suggesting that PL-driven transcription towards the etxB 
gene is selected against (Figure 3). Unexpectedly, when 
cells were grown at 28°C most pYZ17 molecules were 
also found to contain the PL promoter in the OFF 
orientation. This suggests that even the low transcription 
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level from the PL promoter at 28°C is sufficient o select 
against he oy-form of pYZ17. 
Immunogenicity and stability of SL3261 (pYZ17) 
To determine whether pYZ17 was stably maintained 
in vivo, mice were infected i.p. with SL3261(pYZ17), and 
bacteria were recovered from the spleens after 1, 2 and 
3 weeks to determine the fraction of SL3261 cells still 
containing pYZ17 (Figure 4). During this period, pYZ17 
appeared to be completely stable. Five bacterial colonies 
recovered from the spleens were tested for expression of 
CtxB, and turned out to produce the same amount of 
CtxB as the original strain used for infection (results not 
shown). 
4.4  
- -  2 .3  
2 .0  
1.4 
1 2 
Figure 3 Restriction analysis of pYZ17, derived from strains grown at 
28 or 37°C, Plasmid DNA was isolated from SL52&3(pYZ17) grown at 28 
or 37°C, digested with EcoRI and subjected to electrophoresis on a 1% 
agarose gel. Fragments characteristic for plasmids containing the PL 
promoter in ON and OFF orientation are indicated 
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Figure 4 Stability of pYZ17 in vivo; 106 cells of strain SL3261(pYZ17) 
were administered i.p. to Balb/c mice. After 1, 2 and 3 weeks, mice were 
killed and the number of bacteria present in the spleen still containing 
pYZ17 was compared with the total number of bacteria by plating on 
McConkey agar plates with (hatched bars) and without (filled bars) 
ampicillin, respectively. Represented are the geometric means (bars) 
and the corresponding maximum numbers of colony-forming units 
The immunogenicity of SL3261(pYZ 17) was determined 
in mice after oral and i.p. immunization. After oral 
immunization, CtxB-specific IgG and IgA could be 
detected in serum (Figure5a and b, respectively). 
Furthermore, IgA could also be detected in gut washes 
(Figure 6a), indicating that, besides a systemic immune 
response, a mucosal immune response was induced. The 
IgG titres remained high for up to 4 weeks after 
immunization. The IgA titres reached their maximum 
value within 1 week after immunization. During the 
following weeks these titres decreased, but they were 
restored by a booster at week 4. 
In contrast to the oral immunization, o CtxB-specific 
antibodies could be detected after i.p. immunization 
(Figure5). The difference in immune response against 
CtxB observed after oral and i.p. immunization could be 
due to the nature of CtxB, which is known to be a very 
effective mucosal immunogen TM. The immunization 
with CtxB by the oral route may be inherently more 
effective than immunization by the i.p. route. Alternatively 
the i.p. immunization could have been less effective 
because a lower number of cells was administered than 
in oral immunization. To discriminate between these 
possibilities, the antibody responses of the orally and i.p. 
immunized mice against two other bacterial antigens 
were compared. These antigens were lipopolysaccharide 
(LPS) and /~-lactamase, which are expressed on the 
surface and in the periplasmic space of SL3261(pYZ17), 
respectively. Both oral and i.p. immunization resulted in 
the appearance of LPS-specific IgG and IgA in serum 
(Figure 7a and b, respectively). Furthermore, both routes 
of immunization i duced a LPS-specific secretory IgA 
response (Figure6b). Both oral and i.p. immunization 
resulted in a/%lactamase-specific IgG response in serum 
(Figure8), although the i.p. route was clearly more 
effective than the oral route. Specific IgA against 
/~-lactamase could not be detected in the sera or in the 
gut washes after oral or i.p. immunization (results not 
shown). 
These results indicate that for LPS and fl-lactamase 
i.p. immunization was at least as effective as oral 
immunization. Thus the difference between the response 
against CtxB after oral and i.p. immunization is most 
probably due to the fact that CtxB is much more 
immunogenic when presented orally than when presented 
parentally. 
DISCUSSION 
Attenuated Salmonella strains have great potential as 
carriers for the delivery of heterologous antigens to the 
immune system. However, construction of Salmonella- 
recombinant s rains expressing the heterologous antigen 
at levels high enough to induce protective immunity 
without affecting the ability of the strain to invade and 
persist in the host, is a major problem. Expression of 
(high levels of) heterologous antigens may be detrimental 
or toxic for the bacteria, resulting in loss of expression 
in vivo 19'z° or  overattenuation. I  particular, loss of 
expression due to plasmid segregation has been a 
problem/x. For this reason much effort has been put into 
developing systems which increase the stability of the 
DNA expressing the heterologous antigen. Curtiss et 
al. 22-z4 have developed a host-vector system in which 
the antigen expressing DNA is located on a plasmid 
which contains a gene, coding for aspartate 
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Figure 5 Antibody response to CtxB in sera after oral (filled bars) and i.p. (hatched bars) immunization of mice with SL3261(pYZ17). SL3261(pYZ17) 
was administered to Balb/c mice at weeks 0 and 4. Every week, two mice of both groups were bled and their anti-CtxB serum titres were determined. 
Represented are geometric means (bars) and the corresponding maximum titres. The arrow indicates the booster immunization. (a) Anti-CtxB IgG 
response; (b) anti-CtxB IgA response 
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Figure 6 IgA response of four times diluted gut-washes after oral (filled bars) and i.p. (hatched bars) immunization of mice with SL3261(pYZ17). 
SL3261(pYZ17) was administered to Balb/c mice at weeks 0 and 4. Every week, two mice of both groups were killed and their gut washes were tested 
in ELISA. Represented are geometric means (bars) and the corresponding maximum A45o values. The arrow indicates the booster immunization. 
(a) Anti-CtxB response; (b) anti-LPS response 
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Figure 7 Antibody response to LPS in sera after oral (filled bars) and i.p. (hatched bars) immunization of mice with SL3261(pYZ17). SL3261(pYZ17) 
was administered to Balb/c mice at weeks 0 and 4. Every week, two mice of both groups were bled and their anti-LPS serum titres were determined. 
Represented are geometric means (bars) and the corresponding maximum titres. The arrow indicates the booster immunization. (a) Anti-LPS IgG 
response; (b) anti-LPS IgA response 
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Figure 8 IgG response to fl-lactamase in sera after oral (filled bars) 
and i.p. (hatched bars) immunization of mice with SL3261(pYZ17). 
SL3261(pYZ17) was administered to Balb/c mice at weeks 0and 4. Every 
week, two mice of both groups were bled and their anti-fl-lactamase 
serum titres were determined. Values shown are geometric means with 
their maximum titres. The arrow indicates the booster immunization 
fl-semialdehyde dehydrogenase, which is essential for 
growth of the host strain. The stability of the 
antigen-expressing DNA may also be increased by 
integrating it into the chromosome 3'25'26. Although these 
systems have proven to be very useful for the stable 
expression of a number of antigens, they do not allow 
expression of antigens at levels which inhibit cell growth, 
because this will inevitably result in mutational 
alterations to reduce expression 25. This is a major 
problem, because many heterologous antigens are toxic 
for S. typhimurium due to different codon usage or the 
presence of toxic (e.g. hydrophobic) sequences. 
Deliberate reduction of the expression to a level high 
enough to induce an adequate immune response and low 
enough not to affect the fitness of the carrier strain is 
another strategy to obtain stable antigen expression. 
However, this balance between the immunogenicity and 
toxicity will depend on the nature of the antigen and will 
have to be determined anew every time another antigen 
is used. For some antigens this approach will be 
ineffective because, to induce an adequate immune 
response, they require expression at levels that are toxic 
to the producing vaccine strain. 
We have developed a vector for stable expression of 
antigens, based on an invertible PL promoter. The essence 
of the vector is that it directs expression of an antigen 
in only a minor part of the bacterial population. If 
production of the antigen is lethal, the antigen-producing 
bacteria will stop dividing. However, the non-producing 
part of the population will continue to grow and segregate 
antigen-producing cells due to inversion of the PL 
promoter. In this way, dissemination and invasion of the 
total bacterial population will not be affected by antigen 
production (Figure 9). 
To evaluate our system, we used CtxB as a model 
antigen. A plasmid, designated pYZ17, was constructed 
in which expression of the ctxB gene is controlled by an 
invertible PL promoter. It appeared that pYZ17 was 
stably maintained in vitro and in rive. Analysis of pYZ17 
isolated from SL5283 revealed that the copy number of 
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Figure 9 Model illustrating the course of an infection with SL3261 
expressing foreign antigens due to promoter inversions. Circles indicate 
bacteria that do (0) and do not (©) produce antigen. In this figure 
it is assumed that in every generation, 25% of the bacteria will produce 
toxic amounts of antigen due to inversion of the PL promoter and stop 
growing. After oral administration the bacteria will start to colonize the 
gut-associated lymphoid tissue (GALT). The bacteria that produce the 
foreign antigen will stop growing and may even lyse. The non-producing 
bacteria will continue the infection and may colonize the lymph nodes, 
spleen and liver without being affected by production of the antigen. 
During the infection antigen-producing cells will constantly be 
generated due to inversion of the PL promoter 
from pYZl7-ovv. Furthermore, strain SL3261(pYZ17) 
was able to induce an immune response against CtxB. 
The induced CtxB-specific IgG and IgA titres in the 
serum and the presence of IgA in gut washes 
demonstrated that CtxB was efficiently presented in the 
immune system after oral administration of the S. 
typhimurium strain SL3261 harbouring pYZ17 to Balb/c 
mice. The i.p. route turned out to be ineffective to induce 
an immune response against CtxB. This phenomenon 
does not generally apply to other antigens as 
demonstrated bythe fact that antibodies to LPS and the 
pYZ17-encoded/Mactamase were induced more efficiently 
by the i.p. than by the oral route. Others have also found 
that i.p. immunization in general induces stronger 
immune responses than oral administration f recombin- 
ant Salmonella strains zs. The CtxB-pentamer binds 
specifically to the GM 1 gangliosides that are abundantly 
present on mucosal epithelial cells 1 "7,18. This results in a 
very efficient presentation ofCtxB to the immune system 
by the oral route. We speculate that the amount of CtxB 
expressed by SL3261(pYZlT) was too low to induce 
humoral responses after i.p. immunization. In fact, using 
an improved invertible promoter system that results in 
much higher CtxB levels, specific antibodies were also 
induced by i.p. immunization (manuscript inpreparation). 
At present we are evaluating the immune responses to 
a number of HIV-1 and FIV-antigens expressed in 
SL3261 by this improved invertible promoter system. 
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the ON plasmids was substantially ower than the copy 
number of the ovv plasmids. The apparent low copy 
number of pYZl7-oN may be caused by effects at the 
level of cell growth and/or plasmid replication. If the 
production of CtxB inhibits cell growth, bacteria 
containing higher numbers of pYZ17-oy will be 
outgrown by bacteria containing lower numbers of this 
plasmid. However, the observation that the ON/OFF ratio 
is not affected by the large difference in CtxB production 
at 28 and 37°C, nor by deletion of the ctxB gene (result 
not shown) indicates that this effect is of minor 
importance. The alternative explanation for the low copy 
number of pYZ 17-oN, i.e. an effect on plasmid replication, 
seems more likely. For example, transcription from the 
PC promoter in the oN orientation may interfere with 
plasmid replication. A similar phenomenon has been 
described by Strueber and Bujard 27. The observation that 
the growth temperature does not affect he ON/OFF ratio 
suggests that even the leaky transcription at 28°C is 
sufficient o interfere with plasmid replication. We are 
currently addressing these questions. 
In spite of the low copy number of pYZl7-oN, strains 
isolated from the spleens of mice still produced CtxB. 
Apparently pYZI7-oN is stably maintained in the 
bacterial population due to continuous replenishment 
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